Dossier
Johnson & Johnson COVID-19 vaccine
Coverage of Johnson & Johnson COVID-19 vaccine in the Nexus archive.
- A personalized vaccine for melanoma cut the risk of cancer returning after five years
A personalized vaccine for melanoma reduced the risk of cancer recurrence after five years. The content also mentions a Johnson & Johnson COVID-19 vaccine being prepared for a clinical trial in Aurora, Colorado, in 2020.